Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma ...
Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a ...
Eighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the ...
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality. Repligen has inked a $1.5 billion ...
The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line ...
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s ...
After committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its ...
Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. However, at the Alzheimer’s Association International Conference on ...
An unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, ...
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. There’s no doubt that biotech IPOs are back. After a prolonged ...
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results